Maximum quantity allowed is 999
请选择数量
CAS RN: 144689-24-7 | 产品编码: O0507
Olmesartan
×
![]()
×
| 产品编码 | O0507 |
| 纯度/分析方法 | >98.0%(HPLC) |
| 分子式/分子量 | C__2__4H__2__6N__6O__3 = 446.51 |
| 外观与形状（20°C） | 固体 |
| 储存温度 | 冷冻 (<0°C) |
| 应避免的情况 | 加热 |
| 包装和容器 | 100MG-Glass Bottle with Plastic Insert （查看图片） |
| CAS RN | 144689-24-7 |
| Reaxys-RN | 7502669 |
| PubChem物质ID | 354335584 |
| MDL编号 | MFCD00914967 |
技术规格
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 95.0 % |
物性（参考值）
| 熔点 | 177 °C(dec.) |
GHS
相关法规
| RTECS# | NI4014100 |
运输信息
| HS编码* | 2933.99-000 |
应用
Olmesartan: A Selective AT1 Subtype Angiotensin II Receptor Antagonist (“sartan”)
Olmesartan, an active metabolite of olmesartan medoxomil [O0510], is a selective AT1 subtype angiotensin II receptor antagonist (“sartan”), such as candesartan [C2635], eprosartan [E1161], irbesartan [I0859], losartan [L0232], olmesartan [O0507], telmisartan [T2861] and valsartan [V0112].
Angiotensin II is formed from angiotensin I in a reaction catalyzed by angio-tensin converting angiotensin conversion enzyme (ACE), and can active two different receptors, AT1 and AT2, both of which are coupled to G-protein. The vasopressor actions of angiotensin II are mediated through AT1 receptors. Olmesartan and sartans bind selectively to AT1 receptor with almost no binding to AT2 receptor in vascular smooth muscle. Therefore, olmesartan and sartans show blood pressure lowering effect. Recently, some combination agents with a calcium channel antagonist (e.g. amlodipine [A2353], azelnidipine [A2433]) are also used for the treatment of hypertension and cardiovascular disease. (The product is for research purpose only.)
Angiotensin II is formed from angiotensin I in a reaction catalyzed by angio-tensin converting angiotensin conversion enzyme (ACE), and can active two different receptors, AT1 and AT2, both of which are coupled to G-protein. The vasopressor actions of angiotensin II are mediated through AT1 receptors. Olmesartan and sartans bind selectively to AT1 receptor with almost no binding to AT2 receptor in vascular smooth muscle. Therefore, olmesartan and sartans show blood pressure lowering effect. Recently, some combination agents with a calcium channel antagonist (e.g. amlodipine [A2353], azelnidipine [A2433]) are also used for the treatment of hypertension and cardiovascular disease. (The product is for research purpose only.)
References
- In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist (a review)
- Angiotensin II Receptor Antagonists and Angiotensin-Converting Enzyme Inhibitors Lower In Vitro the Formation of Advanced Glycation End Products: Biochemical Mechanisms
- Olmesartan medoxomil, a novel potent angiotensin II blocker (a review)
- H. Koike, T. Konse, T. Sada, T. Ikeda, A. Hyogo, D. Hinman, H. Saito, H. Yanagisawa, Annu. Rep. Sankyo Res. Lab. 2004, 55, 1.
- Calcium channel blocker azelnidipine enhances vascular protective effects of AT1 receptor blocker olmesartan
- Olmesartan/amlodipine: a review of its use in the management of hypertension
- Quantitative determination of olmesartan in human plasma and urine by liquid chromatography coupled to tandem mass spectrometry
- Identification of a degradation product in stressed tablets of olmesartan medoxomil by the complementary use of HPLC hyphenated techniques
参考文献
TCIMail
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。